Masaya Ohtsu

Title: Masaya Ohtsu: Innovator in Cancer Treatment

Introduction

Masaya Ohtsu is a prominent inventor based in Chiba, Japan. He has made significant contributions to the field of pharmaceutical research, particularly in cancer treatment. His innovative work focuses on developing therapeutic compositions that utilize monoclonal antibodies.

Latest Patents

Masaya Ohtsu holds a patent for a therapeutic pharmaceutical composition employing an anti-SLC6A6 antibody. This invention aims to provide a pharmaceutical composition for cancer treatment, which comprises a novel monoclonal antibody binding to SLC6A6 or its extracellular region, along with a chemotherapeutic agent conjugated therewith. The therapeutic method involves using the monoclonal antibody or a therapeutic agent composed of the monoclonal antibody conjugated with a chemotherapeutic agent in combination with a chemotherapeutic agent. This innovative approach offers a pharmaceutical composition that includes an antibody conjugate designed to have a higher affinity than conventional antibodies, targeting native SLC6A6 or its extracellular region, and is conjugated with an anticancer agent effective against cancer and other hyperproliferative diseases. He has 1 patent to his name.

Career Highlights

Masaya Ohtsu is associated with Order-Made Medical Research Inc., where he continues to advance his research in the pharmaceutical field. His work is characterized by a commitment to improving cancer treatment methodologies through innovative approaches.

Collaborations

Masaya Ohtsu collaborates with notable colleagues, including Hiroyuki Satofuka and Kensuke Ohse, who contribute to his research endeavors.

Conclusion

Masaya Ohtsu's contributions to cancer treatment through his innovative patent demonstrate his dedication to advancing medical science. His work exemplifies the potential of targeted therapies in improving patient outcomes.